Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 314

1.

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.

Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, Salgia R.

Oncogenesis. 2019 Sep 4;8(9):49. doi: 10.1038/s41389-019-0159-6.

2.

Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK.

J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30695-1. doi: 10.1016/j.jtho.2019.08.012. [Epub ahead of print]

PMID:
31470129
3.

The Mitochondrion as an Emerging Therapeutic Target in Cancer.

Roth KG, Mambetsariev I, Kulkarni P, Salgia R.

Trends Mol Med. 2019 Jul 18. pii: S1471-4914(19)30171-6. doi: 10.1016/j.molmed.2019.06.009. [Epub ahead of print] Review.

PMID:
31327706
4.

Notch signaling in breast cancer: From pathway analysis to therapy.

Krishna BM, Jana S, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS.

Cancer Lett. 2019 Oct 1;461:123-131. doi: 10.1016/j.canlet.2019.07.012. Epub 2019 Jul 18.

PMID:
31326555
5.

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R.

J Clin Med. 2019 Jul 16;8(7). pii: E1038. doi: 10.3390/jcm8071038.

6.

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.

Ramírez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR.

J Clin Pharmacol. 2019 Jul 5. doi: 10.1002/jcph.1476. [Epub ahead of print]

PMID:
31274208
7.

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.

Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS.

J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30502-7. doi: 10.1016/j.jtho.2019.06.020. [Epub ahead of print]

PMID:
31260832
8.

Targeted Therapies in Non-small-Cell Lung Cancer.

Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R.

Cancer Treat Res. 2019;178:3-43. doi: 10.1007/978-3-030-16391-4_1.

PMID:
31209840
9.

Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.

Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A.

Lung Cancer. 2019 Jul;133:136-143. doi: 10.1016/j.lungcan.2019.05.020. Epub 2019 May 19.

PMID:
31200820
10.

Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.

Singhal SS, Horne D, Singhal J, Vonderfecht S, Salgia R, Awasthi S.

Mol Carcinog. 2019 Aug;58(8):1438-1449. doi: 10.1002/mc.23026. Epub 2019 Apr 21.

PMID:
31006917
11.

Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.

Wang C, Kulkarni P, Salgia R.

Mol Ther Oncolytics. 2019 Mar 19;13:1-6. doi: 10.1016/j.omto.2019.02.001. eCollection 2019 Jun 28. Review.

12.

Early mortality of stage IV non-small cell lung cancer in the United States.

Amini A, Verma V, Glaser SM, Shinde A, Sampath S, Stokes WA, Rusthoven CG, Massarelli E, Salgia R, Gaspar LE, Liu AK.

Acta Oncol. 2019 Aug;58(8):1095-1101. doi: 10.1080/0284186X.2019.1599138. Epub 2019 Apr 8.

PMID:
30958075
13.

Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer.

Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.

Mol Cancer Ther. 2019 Apr;18(4):868. doi: 10.1158/1535-7163.MCT-18-1183. No abstract available.

PMID:
30936412
14.

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.

Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R.

Clin Transl Med. 2019 Mar 18;8(1):9. doi: 10.1186/s40169-019-0225-x. Review.

15.

Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level.

Lin X, Kulkarni P, Bocci F, Schafer NP, Roy S, Tsai MY, He Y, Chen Y, Rajagopalan K, Mooney SM, Zeng Y, Weninger K, Grishaev A, Onuchic JN, Levine H, Wolynes PG, Salgia R, Rangarajan G, Uversky V, Orban J, Jolly MK.

Biomolecules. 2019 Feb 22;9(2). pii: E77. doi: 10.3390/biom9020077.

16.

RLIP: An existential requirement for breast carcinogenesis.

Singhal SS, Salgia R, Singhal S, Horne D, Awasthi S.

Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):281-288. doi: 10.1016/j.bbcan.2019.02.001. Epub 2019 Feb 13. Review.

PMID:
30771458
17.

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.

Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R.

Am J Clin Oncol. 2019 Apr;42(4):337-344. doi: 10.1097/COC.0000000000000508.

PMID:
30741758
18.

RLIP inhibition suppresses breast-to-lung metastasis.

Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS.

Cancer Lett. 2019 Apr 10;447:24-32. doi: 10.1016/j.canlet.2019.01.023. Epub 2019 Jan 23.

PMID:
30684594
19.

The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.

Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R.

Bioinformatics. 2019 Aug 15;35(16):2738-2748. doi: 10.1093/bioinformatics/bty1021.

20.

Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2018 Dec 1;24(23):6099. doi: 10.1158/1078-0432.CCR-18-3194. No abstract available.

PMID:
30510088

Supplemental Content

Loading ...
Support Center